Lixte Biotechnology closes ~$16.6M registered direct offering of common stock and warrants

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Gross proceeds of ~$16.6 million from sale of 2,625,362 shares and pre-funded warrants.
Offering priced at $6.31 per common share and $6.3099 per pre-funded warrant.
Pre-funded warrants exercisable immediately at $0.0001 per share.
Net proceeds to be used for general corporate purposes and working capital.
Offering closed on June 4, 2026 under existing shelf registration statement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Purchase Agreement with certain accredited investors valued at approximately $16.6 million (effective 2026-06-02).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $16.6 million
Effective: 2026-06-02

Exact text from the filing

On June 2, 2026, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 2,366,503 shares (the “Common Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”), and Pre-Funded Warrants (“Pre-Funded Warrants”) to purchase 258,859 shares of Common Stock, at an offering price of $6.31 per share (or $6.30 per Pre-Funded Warrant).

View on SEC.gov

802 material agreements filed in the last 30 days. Browse all material agreements →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-027307

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.